Tempest Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Tempest Therapeutics Inc TPST.OQ reported a quarterly adjusted loss of $3.16​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-4.68. The mean expectation of four analysts for the quarter was for a loss of $3.29 per share. Wall Street expected results to range from $-4.42 to $-2.47 per share.

• Reported revenue was zero​; analysts expected zero.

• Tempest Therapeutics Inc's reported EPS for the quarter was a loss of $3.16​.

• The company reported a quarterly loss of $10.86 million.

• Tempest Therapeutics Inc shares had fallen by 32.2% this quarter and lost 40.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Tempest Therapeutics Inc is $65.00

This summary was machine generated from LSEG data May 16 at 11:59 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)